Asia
Mid-February had a solid number of clinical trial announcements. Here’s a look.
In a breakthrough study, scientists from Japan find the potential of an opioid drug to help numb fear memory
Teva’s deutetrabenazine for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome did not meet the primary endpoint in the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials.
Padcev, which was approved by the U.S. Food and Drug Administration in December, secured Breakthrough Therapy designation for the treatment of patients with another type of bladder cancer.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
The U.S. Food and Drug Administration issued a statement on Friday outlining what the agency is doing at home and abroad in response to the outbreak, which has infected more than 73,000 people worldwide.
The trial’s goal is to test more than 700 patients infected with the coronavirus, but at this point, there have been fewer than 200 people recruited.
Brain eating amoeba treatment is crucial in the current world as infections are rising. Moreover, it is very deadly, killing about 97% of infected patients.
It was a very busy week for clinical trial news. Here’s a look.
These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.
PRESS RELEASES